We would like to inform patients that Astra Zeneca vaccinations are still going ahead. We hope the below information and update from the Cheshire CCG helps alleviate any concerns that patients may have.
Safety of Oxford/AstraZeneca COVID-19 vaccine
Vaccination centres may receive questions about the safety of the Oxford/AstraZeneca COVID-19 vaccine after several countries – as a precaution – suspended use over concerns about possible side effects.
The World Health Organisation and European Medicines Agency both say there is no indication of a link between the vaccine and reports of blood clots.
In a statement, Dr Phil Bryan, MHRA Vaccines Safety Lead, said: “Vaccine safety is of paramount importance and we continually monitor the safety of vaccines to ensure that the benefits outweigh any potential risks. It has not been confirmed that the report of a blood clot, in Denmark, was caused by the COVID-19 Vaccine AstraZeneca. The Danish, Norwegian and and Icelandic authorities’ action to temporarily suspend use of the vaccine is precautionary whilst they investigate. Blood clots can occur naturally and are not uncommon.
“More than 11 million doses of the COVID-19 Vaccine AstraZeneca vaccine have now been administered across the UK. Reports of blood clots received so far are not greater than the number that would have occurred naturally in the vaccinated population. The safety of the public will always come first. We are keeping this issue under close review but available evidence does not confirm that the vaccine is the cause. People should still go and get their COVID-19 vaccine when asked to do so.”
A further statement from AstraZeneca provides additional detail including: “A careful review of all available safety data of more than 17 million people vaccinated in the European Union (EU) and UK with COVID-19 Vaccine AstraZeneca has shown no evidence of an increased risk of pulmonary embolism, deep vein thrombosis (DVT) or thrombocytopenia, in any defined age group, gender, batch or in any particular country.
“So far across the EU and UK, there have been 15 events of DVT and 22 events of pulmonary embolism reported among those given the vaccine, based on the number of cases the company has received as of 8 March. This is much lower than would be expected to occur naturally in a general population of this size and is similar across other licensed COVID-19 vaccines.”